Improving Survival In Oncogene Driven Lung Cancer

Join us for a conversation with internationally recognized Medical Oncologists and researchers, Professor Ben Solomon & Associate Professor Tom John as they discuss the increased survival benefits for patients with oncogene driven lung cancer and how novel treatments are contributing.

Oncogenes discussed include EGFR & osimertinib; ALK & brigatinib, alectinib, lorlatinib; ROS1 & crizotinib, entrectinib; KRAS & sotorasib; G12C; Exon20 insertions & poziotinib, amivantamab, RET & selpercatinib, pralcetinib. Also discussed – the importance of the move beyond single gene testing to panels and NGS is important to maximise turn-around times and the efficient utilization of clinical samples.

---------------

Support TOGA

Thank you for listening to Conversations in Lung Cancer Research. If you enjoyed this episode, please rate and review us on Apple Podcasts or Spotify.

---------------

Connect with TOGA

Attend an Event: https://thoraciconcology.org.au/events/

Become a Member: Join the TOGA community at https://thoraciconcology.org.au/membership/

Donate: Support our research and treatment initiatives at https://thoraciconcology.org.au/support-us/donate/

Follow Us

LinkedIn: https://www.linkedin.com/company/thoracic-oncology-group-of-australasia/

X (Twitter): https://x.com/TOGAANZ

Instagram: https://www.instagram.com/togaanz/

YouTube: https://www.youtube.com/@Thoracic_Oncology

---------------

Acknowledgement of Country

The Thoracic Oncology Group of Australasia Limited acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait cultures; and to Elders past and present.